BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

Free Newsletters
My Subscriptions

News by Subject
News by Disease
News by Date
Search News
Post Your News

Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Pharm Country
  Bio NC
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™


Company Profiles

Research Store

Research Events
Post an Event
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile


Depomed, Inc. 

7999 Gateway Boulevard
Suite 300
Newark  California  94560  U.S.A.
Phone: 510-744-8000 Fax: 510-744-8001


View Clinical Trials from BioPharm Insight

Depomed, Inc. is a specialty pharmaceutical company focused on developing and commercializing products to treat pain and other central nervous system conditions. The company was founded in 1995 and has established itself by developing and incorporating promising technology into differentiated therapeutic products, taking those products through clinical approval, and building a strong market presence. The company currently markets four FDA-approved products, Gralise® (gabapentin) tablets for the management of Postherpetic Neuralgia (PHN), Cambia® (diclofenac potassium for oral solution) for acute treatment of migraine attacks with or without aura in adults 18 years of age or older, Zipsor® (diclofenac potassium) liquid filled capsules for relief of mild to moderate acute pain, and Lazanda® (fentanyl) nasal spray CII for the management of breakthrough pain in cancer patients. See Important Safety Information for Gralise, Cambia, Zipsor, and Lazanda.

In addition to its ability to develop and commercialize new drugs, Depomed also has successfully developed and licensed its unique drug-delivery technology, Acuform®. This patented oral-delivery technology allows for the targeted, extended release of pharmaceutical compounds into the upper gastrointestinal tract. We have licensed Acuform technology to six pharmaceutical partners and the technology is currently being used in four marketed drugs, including Gralise.

Going forward, the company’s strategy is to continue to identify, license and develop new products that offer enhanced therapeutic options to patient populations that may be underserved by existing therapies. In addition, the company seeks to continue to leverage its innovative Acuform technology to generate a complementary stream of license revenue.

 Key Statistics

Ownership: Public

Web Site: Depomed, Inc.
Symbol: DEPO


Drug Delivery

 Company News
Depomed, Inc. (DEPO) Smacks Down $1.05 Billion for Johnson & Johnson (JNJ)'s Pain Drug Franchise 1/15/2015 4:11:10 PM
Depomed, Inc. (DEPO) To Present At Piper Jaffray 26th Annual Healthcare Conference 11/21/2014 9:22:45 AM
Depomed, Inc. (DEPO)To Present At Stifel 2014 Healthcare Conference 11/12/2014 8:09:49 AM
Depomed, Inc. (DEPO) Reports Third Quarter 2014 Financial Results 11/6/2014 7:30:40 AM
Depomed, Inc. (DEPO) To Report Third Quarter Fiscal Year 2014 Financial Results On Wednesday, November 5, 2014 10/28/2014 7:17:07 AM
Depomed, Inc. (DEPO) Announces Pricing Of Upsized $300 Million Convertible Senior Notes Due 2021 9/5/2014 1:01:31 PM
Depomed, Inc. (DEPO) Summary Judgment Motion Granted In Suit Against FDA Seeking Orphan Drug Exclusivity For Gralise® (Gabapentin) 9/5/2014 12:56:26 PM
Depomed, Inc. (DEPO) Announces Offering Of $230 Million Convertible Senior Notes Due 2021 9/3/2014 4:15:51 PM
Depomed, Inc. (DEPO) To Present At Morgan Stanley 2014 Global Healthcare Conference 8/26/2014 8:58:29 AM
Depomed, Inc. (DEPO) Prevails in Gralise® ANDA Litigation Blocking Generic Entry Until 2024 8/19/2014 10:39:25 AM